Dihexa vs Tirzepatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dihexa
Dihexa is a nootropic peptide derived from angiotensin IV. It has shown remarkable cognitive-enhancing properties in animal studies, being described as potentially millions of times more potent than BDNF.
Full details →Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →Side-by-Side Comparison
| Aspect | Dihexa | Tirzepatide |
|---|---|---|
| Mechanism | Acts as a hepatocyte growth factor (HGF) potentiator by binding to its receptor c-Met. Promotes synaptogenesis, neuronal survival, and cognitive enhancement through this pathway. | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. |
| Typical Dosage | Research dosing is highly variable due to extreme potency. Typical range: 10-40mg orally or sublingually. Start with lowest doses due to potency. | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. |
| Administration | Can be taken orally, sublingually, or intranasally. Extremely potent - careful dosing is essential. Best used cyclically. | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. |
| Side Effects | Limited human data. Reported effects include headache, temporary brain fog during adjustment, and potential mood changes. | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. |
| Best For |